Does Dr. FARIBORZ REZAI have financial conflicts of interest?

Dr. FARIBORZ REZAI (M.D.) has received a total of $1,639,791 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $1,639,791 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. FARIBORZ REZAI?

According to CMS Open Payments data, Dr. FARIBORZ REZAI received funding from ASTRAZENECA PHARMACEUTICALS ($368,229), GILEAD SCIENCES ($237,175), and CSL BEHRING ($233,726).

Does Dr. FARIBORZ REZAI receive research grants or speaking fees?

Dr. FARIBORZ REZAI has received $1,639,791 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. FARIBORZ REZAI

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Critical Care Medicine

Practice Location: LIVINGSTON, NJ 07039

NPI Number: 1942249313

LIFETIME INDUSTRY VALUE

$1,639,791

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. REZAI is a verified Internal Medicine, Critical Care Medicine practitioner based in LIVINGSTON, NJ.

Between 2021 and 2024, Dr. REZAI had an overall industry promotional and research financial footprint of $1,639,791 as recorded in the federal CMS Open Payments database.

$1,639,791 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. REZAI's primary funding source is ASTRAZENECA PHARMACEUTICALS, which accounts for $368,229 (representing 22.5% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ASTRAZENECA PHARMACEUTICALS

Rank 1

$368,229

22.5%

GILEAD SCIENCES

Rank 2

$237,175

14.5%

CSL BEHRING

Rank 3

$233,726

14.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.